Literature DB >> 21367889

Deletion of major nonessential genomic regions in the vaccinia virus Lister strain enhances attenuation without altering vaccine efficacy in mice.

Julie Dimier1, Audrey Ferrier-Rembert, Karine Pradeau-Aubreton, Matthias Hebben, Danièle Spehner, Anne-Laure Favier, Danielle Gratier, Daniel Garin, Jean-Marc Crance, Robert Drillien.   

Abstract

The vaccinia virus (VACV) Lister strain was one of the vaccine strains that enabled smallpox eradication. Although the strain is most often harmless, there have been numerous incidents of mild to life-threatening accidents with this strain and others. In an attempt to further attenuate the Lister strain, we investigated the role of 5 genomic regions known to be deleted in the modified VACV Ankara (MVA) genome in virulence in immunodeficient mice, immunogenicity in immunocompetent mice, and vaccine efficacy in a cowpox virus challenge model. Lister mutants were constructed so as to delete each of the 5 regions or various combinations of these regions. All of the mutants replicated efficiently in tissue culture except region I mutants, which multiplied more poorly in human cells than the parental strain. Mutants with single deletions were not attenuated or only moderately so in athymic nude mice. Mutants with multiple deletions were more highly attenuated than those with single deletions. Deleting regions II, III, and V together resulted in total attenuation for nude mice and partial attenuation for SCID mice. In immunocompetent mice, the Lister deletion mutants induced VACV specific humoral responses equivalent to those of the parental strain but in some cases lower cell-mediated immune responses. All of the highly attenuated mutants protected mice from a severe cowpox virus challenge at low vaccine doses. The data suggest that several of the Lister mutants combining multiple deletions could be used in smallpox vaccination or as live virus vectors at doses equivalent to those used for the traditional vaccine while displaying increased safety.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21367889      PMCID: PMC3126188          DOI: 10.1128/JVI.02359-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  74 in total

1.  Identification of the orthopoxvirus p4c gene, which encodes a structural protein that directs intracellular mature virus particles into A-type inclusions.

Authors:  Terry A McKelvey; Stanley C Andrews; Sara E Miller; Caroline A Ray; David J Pickup
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

2.  Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge.

Authors:  Linda S Wyatt; Patricia L Earl; Leigh Anne Eller; Bernard Moss
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-11       Impact factor: 11.205

3.  Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses.

Authors:  Igor M Belyakov; Patricia Earl; Amiran Dzutsev; Vladimir A Kuznetsov; Michael Lemon; Linda S Wyatt; James T Snyder; Jeffrey D Ahlers; Genoveffa Franchini; Bernard Moss; Jay A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-17       Impact factor: 11.205

4.  The vaccinia virus kelch-like protein C2L affects calcium-independent adhesion to the extracellular matrix and inflammation in a murine intradermal model.

Authors:  Marta Pires de Miranda; Patrick C Reading; David C Tscharke; Brendan J Murphy; Geoffrey L Smith
Journal:  J Gen Virol       Date:  2003-09       Impact factor: 3.891

5.  The block in assembly of modified vaccinia virus Ankara in HeLa cells reveals new insights into vaccinia virus morphogenesis.

Authors:  M Carmen Sancho; Sibylle Schleich; Gareth Griffiths; Jacomine Krijnse-Locker
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

6.  Plasma membrane budding as an alternative release mechanism of the extracellular enveloped form of vaccinia virus from HeLa cells.

Authors:  Andrea Meiser; Carmen Sancho; Jacomine Krijnse Locker
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

7.  Induction of potent humoral and cell-mediated immune responses by attenuated vaccinia virus vectors with deleted serpin genes.

Authors:  Fatema A Legrand; Paulo H Verardi; Leslie A Jones; Kenneth S Chan; Yue Peng; Tilahun D Yilma
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

8.  Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox.

Authors:  Patricia L Earl; Jeffrey L Americo; Linda S Wyatt; Leigh Anne Eller; J Charles Whitbeck; Gary H Cohen; Roselyn J Eisenberg; Christopher J Hartmann; David L Jackson; David A Kulesh; Mark J Martinez; David M Miller; Eric M Mucker; Joshua D Shamblin; Susan H Zwiers; John W Huggins; Peter B Jahrling; Bernard Moss
Journal:  Nature       Date:  2004-03-11       Impact factor: 49.962

9.  Dendritic cells from mice neonatally vaccinated with modified vaccinia virus Ankara transfer resistance against herpes simplex virus type I to naive one-week-old mice.

Authors:  Marco Franchini; Hanspeter Hefti; Sabine Vollstedt; Bettina Glanzmann; Matthias Riesen; Mathias Ackermann; Paul Chaplin; Ken Shortman; Mark Suter
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

10.  Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel.

Authors:  Jeffrey S Halsell; James R Riddle; J Edwin Atwood; Pierce Gardner; Robert Shope; Gregory A Poland; Gregory C Gray; Stephen Ostroff; Robert E Eckart; Duane R Hospenthal; Roger L Gibson; John D Grabenstein; Mark K Arness; David N Tornberg
Journal:  JAMA       Date:  2003-06-25       Impact factor: 56.272

View more
  11 in total

1.  Repair of a previously uncharacterized second host-range gene contributes to full replication of modified vaccinia virus Ankara (MVA) in human cells.

Authors:  Chen Peng; Bernard Moss
Journal:  Proc Natl Acad Sci U S A       Date:  2020-02-04       Impact factor: 11.205

2.  CD8 T cells are essential for recovery from a respiratory vaccinia virus infection.

Authors:  John Goulding; Rebecka Bogue; Vikas Tahiliani; Michael Croft; Shahram Salek-Ardakani
Journal:  J Immunol       Date:  2012-07-23       Impact factor: 5.422

3.  The vaccinia virus O1 protein is required for sustained activation of extracellular signal-regulated kinase 1/2 and promotes viral virulence.

Authors:  Marc Schweneker; Susanne Lukassen; Michaela Späth; Michael Wolferstätter; Eveline Babel; Kay Brinkmann; Ursula Wielert; Paul Chaplin; Mark Suter; Jürgen Hausmann
Journal:  J Virol       Date:  2011-12-14       Impact factor: 5.103

4.  Attenuation and immunogenicity of host-range extended modified vaccinia virus Ankara recombinants.

Authors:  Sharon Melamed; Linda S Wyatt; Robin J Kastenmayer; Bernard Moss
Journal:  Vaccine       Date:  2013-08-06       Impact factor: 3.641

Review 5.  The evolution of poxvirus vaccines.

Authors:  Lucas Sánchez-Sampedro; Beatriz Perdiguero; Ernesto Mejías-Pérez; Juan García-Arriaza; Mauro Di Pilato; Mariano Esteban
Journal:  Viruses       Date:  2015-04-07       Impact factor: 5.048

6.  Attenuation of monkeypox virus by deletion of genomic regions.

Authors:  Juan G Lopera; Elizabeth A Falendysz; Tonie E Rocke; Jorge E Osorio
Journal:  Virology       Date:  2014-12-01       Impact factor: 3.616

Review 7.  The French Armed Forces Virology Unit: A Chronological Record of Ongoing Research on Orthopoxvirus.

Authors:  Déborah Delaune; Frédéric Iseni; Audrey Ferrier-Rembert; Christophe N Peyrefitte; Olivier Ferraris
Journal:  Viruses       Date:  2017-12-23       Impact factor: 5.048

8.  Cowpox Virus: A New and Armed Oncolytic Poxvirus.

Authors:  Marine Ricordel; Johann Foloppe; Christelle Pichon; Nathalie Sfrontato; Delphine Antoine; Caroline Tosch; Sandrine Cochin; Pascale Cordier; Eric Quemeneur; Christelle Camus-Bouclainville; Stéphane Bertagnoli; Philippe Erbs
Journal:  Mol Ther Oncolytics       Date:  2017-08-24       Impact factor: 7.200

9.  Novel Nonreplicating Vaccinia Virus Vector Enhances Expression of Heterologous Genes and Suppresses Synthesis of Endogenous Viral Proteins.

Authors:  Linda S Wyatt; Wei Xiao; Jeffrey L Americo; Patricia L Earl; Bernard Moss
Journal:  mBio       Date:  2017-06-06       Impact factor: 7.867

10.  SPI-1 is a missing host-range factor required for replication of the attenuated modified vaccinia Ankara (MVA) vaccine vector in human cells.

Authors:  Ruikang Liu; Jorge D Mendez-Rios; Chen Peng; Wei Xiao; Andrea S Weisberg; Linda S Wyatt; Bernard Moss
Journal:  PLoS Pathog       Date:  2019-05-30       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.